Direxion Daily S&P Biotech Bull 3X ETF
LABU
2 hedge funds and large institutions have $2.61M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.11% more ownership
Funds ownership: 0% → 0.11% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$1.86M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$560K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citigroup
New York
| $2M | +$1.86M | +525 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $604K | +$560K | +158 | New |
|
LABU Hedge Fund Activity: Q2 2015 in Review
2 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2015, worth a combined $2.61M.
Buyers outnumbered sellers: 2 funds opened new LABU positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $1.86M.
- 2 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $2.61M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2015.
- 2 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2015 and 0 closed out, a net change of +2 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2015 was Citigroup, an estimated $1.86M added.
Based on aggregated 13F filings for Q2 2015.